Literature DB >> 26535023

Parkinson's Disease and Its Management: Part 3: Nondopaminergic and Nonpharmacological Treatment Options.

George DeMaagd, Ashok Philip.   

Abstract

This installment of a five-part series reviews the role of nondopaminergic pharmacotherapies and adjunctive options-such as monoamine oxidase type B inhibitors, catechol-O-methyltransferase inhibitors, and anticholinergic agents-in managing Parkinson's disease. Nonpharmacological treatments are also explored.

Entities:  

Year:  2015        PMID： 26535023      PMCID： PMC4606857     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  124 in total

1.  A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study.

Authors: 
Journal:  Arch Neurol       Date:  2002-12

Review 2.  The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease.

Authors:  Susan H Fox; Regina Katzenschlager; Shen-Yang Lim; Bernard Ravina; Klaus Seppi; Miguel Coelho; Werner Poewe; Olivier Rascol; Christopher G Goetz; Cristina Sampaio
Journal:  Mov Disord       Date:  2011-10       Impact factor: 10.338

Review 3.  Pharmacological treatment of Parkinson disease: a review.

Authors:  Barbara S Connolly; Anthony E Lang
Journal:  JAMA       Date:  2014 Apr 23-30       Impact factor: 56.272

4.  Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial.

Authors:  Stéphane Palfi; Jean Marc Gurruchaga; G Scott Ralph; Helene Lepetit; Sonia Lavisse; Philip C Buttery; Colin Watts; James Miskin; Michelle Kelleher; Sarah Deeley; Hirokazu Iwamuro; Jean Pascal Lefaucheur; Claire Thiriez; Gilles Fenelon; Cherry Lucas; Pierre Brugières; Inanna Gabriel; Kou Abhay; Xavier Drouot; Naoki Tani; Aurelie Kas; Bijan Ghaleh; Philippe Le Corvoisier; Patrice Dolphin; David P Breen; Sarah Mason; Natalie Valle Guzman; Nicholas D Mazarakis; Pippa A Radcliffe; Richard Harrop; Susan M Kingsman; Olivier Rascol; Stuart Naylor; Roger A Barker; Philippe Hantraye; Philippe Remy; Pierre Cesaro; Kyriacos A Mitrophanous
Journal:  Lancet       Date:  2014-01-10       Impact factor: 79.321

5.  Amantadine HCL (Symmetrel) and its relation to Levo-Dopa in the treatment of Parkinson's disease.

Authors:  R S Schwab; A C England
Journal:  Trans Am Neurol Assoc       Date:  1969

Review 6.  Designing prodrugs for the treatment of Parkinson's disease.

Authors:  Piera Sozio; Laura Serafina Cerasa; Anna Abbadessa; Antonio Di Stefano
Journal:  Expert Opin Drug Discov       Date:  2012-04-12       Impact factor: 6.098

7.  Serum urate and the risk of Parkinson's disease: results from a meta-analysis.

Authors:  Chunhong Shen; Yi Guo; Wei Luo; Chen Lin; Meiping Ding
Journal:  Can J Neurol Sci       Date:  2013-01       Impact factor: 2.104

Review 8.  Adenosine A2A receptor antagonist istradefylline 20 versus 40 mg/day as augmentation for Parkinson's disease: a meta-analysis.

Authors:  Chuan Zhu; Guowei Wang; Jinqing Li; Li Chen; Chaoli Wang; Yajie Wang; Ping Lin; Hong Ran
Journal:  Neurol Res       Date:  2014-04-13       Impact factor: 2.448

Review 9.  Adenosine A2A antagonists in Parkinson's disease: what's next?

Authors:  Patrick Hickey; Mark Stacy
Journal:  Curr Neurol Neurosci Rep       Date:  2012-08       Impact factor: 5.081

10.  Use of calcium channel blockers and Parkinson's disease.

Authors:  Björn Pasternak; Henrik Svanström; Nete M Nielsen; Lars Fugger; Mads Melbye; Anders Hviid
Journal:  Am J Epidemiol       Date:  2012-03-01       Impact factor: 4.897
View more
  5 in total

1.  Non-Oral Drug Delivery in Parkinson's Disease: Current Applications and Future.

Authors:  Meliha Güneş; Sinem Yaprak Karavana
Journal:  Turk J Pharm Sci       Date:  2022-06-27

2.  Effects of bilateral subthalamic nucleus deep brain stimulation on motor symptoms in Parkinson's disease: a retrospective cohort study.

Authors:  Guo-Xiong Cheng; Shu-Bin Yin; Ying-Hao Yang; Yuan-Hu Hu; Chih-Yang Huang; Qian-Ming Yao; Wei-Jen Ting
Journal:  Neural Regen Res       Date:  2021-05       Impact factor: 5.135

3.  Perceived exercise habits of individuals with Parkinson's disease living in the community.

Authors:  Jordana Lockwich; Kate Schwartzkopf-Phifer; Camille Skubik-Peplaski; Richard D Andreatta; Patrick Kitzman
Journal:  Clin Park Relat Disord       Date:  2021-12-17

4.  Long-Term Persistence and Monotherapy with Device-Aided Therapies: A Retrospective Analysis of an Israeli Cohort of Patients with Advanced Parkinson's Disease.

Authors:  Avner Thaler; Yael Barer; Ruth Gross; Raanan Cohen; Lars Bergmann; Yash J Jalundhwala; Nir Giladi; Gabriel Chodick; Varda Shalev; Tanya Gurevich
Journal:  Adv Ther       Date:  2022-03-05       Impact factor: 3.845

5.  Intraperitoneal Administration of Forskolin Reverses Motor Symptoms and Loss of Midbrain Dopamine Neurons in PINK1 Knockout Rats.

Authors:  Emmanuel Vazquez-Mayorga; Mariana Grigoruta; Raul Dagda; Bridget Martinez; Ruben K Dagda
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.